MiNK Therapeutics, Inc. (INKT) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Mink Therapeutics' fourth quarter and year-end 2025 financial results conference call. All participants will be in a listen-only mode until the question-and-answer session. As a reminder, this event is being recorded. If anyone has any objections, you may disconnect at this time. I would now like to turn the conference over to Stephanie Perrin-Nacar, Chief Communications Officer. Please go ahead. Thank you, Operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory and commercial plans, timelines for data releases, and partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our SEC filings available on our website for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer, Dr. Terese Hammond, Head of Development, and Melissa Orell, Principal Financial and Accounting Officer. I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter. Dr. Buell? Thank you, Stephanie. Good morning, everyone. For those new to Mink Therapeutics, we are advancing a clinically validated allogeneic and variant natural killer T cell platform, one that is fundamentally differentiated in its ability to restore and coordinate immune function across diseases or even in immune failure. And unlike conventional cell therapies, our mink INKT cells are off the shelf. They are administered without lymphodepletion, without HLA matching. And we've demonstrated clinical activity with a very favorable safety profile. Mink cells are now...